Suvorexant, a medication used to treat insomnia, was developed in the 2000s and approved for medical use in the 2010s. Its history is marked by its effectiveness in promoting sleep onset and maintenance, but also by considerations regarding next-day drowsiness and potential interactions with other central nervous system depressants, leading to cautious prescribing guidelines. Suvorexant, an orexin receptor antagonist used to treat insomnia, was approved in the United States in 2014 and is included in treatment plans for adults with sleep difficulties. Its development featured a focus on targeting the orexin system rather than traditional sedative pathways, and its approval included clinical monitoring programs to evaluate safety and efficacy in real-world use.
BRAND NAMES
Belsomra – prescription medication for insomnia.
MECHANISM OF ACTION
Suvorexant is an orexin receptor antagonist that selectively inhibits both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the brain. Orexins are neuropeptides responsible for promoting wakefulness, so by blocking these receptors, Suvorexant reduces the brain’s wakefulness signals, helping patients both fall asleep and stay asleep. Unlike traditional sedative-hypnotics such as benzodiazepines or Z-drugs, Suvorexant does not directly enhance GABAergic activity, which contributes to a lower risk of dependence and certain cognitive side effects. In essence, Suvorexant works by quieting the body’s arousal system rather than directly sedating the central nervous system.
PHARMACOKINETICS
Absorption
Suvorexant is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 2 hours after a dose. Its absorption is slightly increased when taken with a high-fat meal, but this does not significantly affect its overall effectiveness. The drug has an oral bioavailability of about 82%, allowing consistent therapeutic levels in the bloodstream.
Distribution
The mean volume of distribution for Suvorexant is approximately 49 liters (49 L), indicating that it distributes into tissues rather than staying restricted to the plasma. It is highly lipophilic, crosses the blood-brain barrier, and exhibits extensive plasma protein binding of over 99%.
Metabolism
Suvorexant is mainly metabolized in the liver by the enzyme CYP3A4. It is converted into inactive metabolites, which are then eliminated from the body. Medications that affect CYP3A4 can alter Suvorexant levels, so careful monitoring or dose adjustment may be needed when taken with such drugs.
Elimination
Suvorexant is primarily excreted in the feces(about 66%) and partially in the urine (around 23%) as inactive metabolites. Its half-life is approximately 12 hours, allowing for once-nightly dosing. The drug is eliminated mainly via hepatic metabolism, so liver function can affect its clearance.
PHARMACODYNAMICS
Suvorexant promotes sleep by blocking orexin-1 and orexin-2 receptors, which are responsible for maintaining wakefulness. This inhibition decreases arousal signals in the brain, helping patients fall asleep faster and stay asleep longer. Unlike traditional sedatives, Suvorexant does not directly enhance GABA activity, resulting in a lower risk of dependence and cognitive impairment while effectively improving sleep quality.
ADMINISTRATION
Suvorexant is administered orally as a tablet, usually once nightly within 30 minutes of bedtime. It should be taken only when the patient can get a full night’s sleep (at least 7 hours). The medication can be taken with or without food, though high-fat meals may delay its onset of action. Dosing is typically 5–20 mg, adjusted based on efficacy and tolerability.
DOSAGE AND STRENGTH
Suvorexant is available in tablet form with the following strengths: 5 mg, 10 mg, 15 mg, and 20 mg. The usual starting dose is 10 mg once nightly, taken within 30 minutes of bedtime. Depending on efficacy and tolerability, the dose can be increased to 20 mg or decreased to 5 mg for older adults or those sensitive to side effects.
DRUG INTERACTIONS
Suvorexant is mainly broken down by CYP3A4, so drugs that affect this enzyme can change its levels. Inhibitors like ketoconazole can increase sedation, while inducers like rifampin can reduce its effectiveness. Combining Suvorexant with other sedatives or alcohol can also increase drowsiness, so caution is needed.
FOOD INTERACTIONS
Taking Suvorexant with a high-fat meal can delay its absorption and the onset of sleep, though it does not significantly reduce overall effectiveness. It can be taken with or without food, but for faster sleep onset, it is usually recommended to take the medication on an empty stomach or avoid heavy meals before bedtime.
CONTRAINDICATIONS
Suvorexant should not be used in patients with narcolepsy, severe liver problems, or a knownallergy to the drug. Caution is also needed in older adults, those with breathing issues, or a history of substance dependence.
SIDE EFFECTS
Common: drowsiness, headache, dizziness, abnormal dreams
Next-day effects: grogginess, impaired alertness
Less common/serious: sleep paralysis, hallucinations, sleepwalking or other complex sleep behaviors
Generalnote: side effects are usually mild to moderate and may decrease with continued use
TOXICITY
Suvorexant has a low risk of severe toxicity at normal doses. Overdose may lead to excessive sleepiness, dizziness, or impaired coordination, but serious complications are uncommon. Supportive care is usually enough if an overdose occurs.
